Stock Analysis on Net
Stock Analysis on Net

Pfizer Inc. (NYSE:PFE)

Paying users zone. Data is hidden behind: .


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Apple Pay Google Pay
Verified by Visa MasterCard SecureCode American Express SafeKey

This is a one-time payment. There is no automatic renewal.

Common-Size Balance Sheet: Liabilities and Stockholders’ Equity
Quarterly Data

Beginner level

Pfizer Inc., common-size consolidated balance sheet: liabilities and stockholders’ equity (quarterly data)

Microsoft Excel LibreOffice Calc
Sep 27, 2020 Jun 28, 2020 Mar 29, 2020 Dec 31, 2019 Sep 29, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jul 1, 2018 Apr 1, 2018 Dec 31, 2017 Oct 1, 2017 Jul 2, 2017 Apr 2, 2017 Dec 31, 2016 Oct 2, 2016 Jul 3, 2016 Apr 3, 2016 Dec 31, 2015 Sep 27, 2015 Jun 28, 2015 Mar 29, 2015
Short-term borrowings, including current portion of long-term debt
Trade accounts payable
Dividends payable
Income taxes payable
Accrued compensation and related items
Other current liabilities
Current liabilities
Long-term debt, excluding current portion
Pension benefit obligations, net
Postretirement benefit obligations, net
Noncurrent deferred tax liabilities
Other taxes payable
Other noncurrent liabilities
Noncurrent liabilities
Total liabilities
Preferred stock
Common stock
Additional paid-in capital
Treasury stock
Retained earnings
Accumulated other comprehensive loss
Total Pfizer Inc. shareholders’ equity
Equity attributable to noncontrolling interests
Total equity
Total liabilities and equity

Based on: 10-Q (filing date: 2020-11-05), 10-Q (filing date: 2020-08-06), 10-Q (filing date: 2020-05-07), 10-K (filing date: 2020-02-27), 10-Q (filing date: 2019-11-07), 10-Q (filing date: 2019-08-08), 10-Q (filing date: 2019-05-09), 10-K (filing date: 2019-02-28), 10-Q (filing date: 2018-11-08), 10-Q (filing date: 2018-08-09), 10-Q (filing date: 2018-05-10), 10-K (filing date: 2018-02-22), 10-Q (filing date: 2017-11-09), 10-Q (filing date: 2017-08-10), 10-Q (filing date: 2017-05-11), 10-K (filing date: 2017-02-23), 10-Q (filing date: 2016-11-10), 10-Q (filing date: 2016-08-11), 10-Q (filing date: 2016-05-12), 10-K (filing date: 2016-02-29), 10-Q (filing date: 2015-11-05), 10-Q (filing date: 2015-08-06), 10-Q (filing date: 2015-05-07).

Balance sheet item Description The company
Current liabilities Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. Pfizer Inc.’s current liabilities as a percentage of total liabilities and equity decreased from Q1 2020 to Q2 2020 but then slightly increased from Q2 2020 to Q3 2020.
Noncurrent liabilities Amount of obligation due after one year or beyond the normal operating cycle, if longer. Pfizer Inc.’s noncurrent liabilities as a percentage of total liabilities and equity increased from Q1 2020 to Q2 2020 but then slightly decreased from Q2 2020 to Q3 2020.
Total liabilities Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future. Pfizer Inc.’s total liabilities as a percentage of total liabilities and equity increased from Q1 2020 to Q2 2020 but then slightly decreased from Q2 2020 to Q3 2020.
Total Pfizer Inc. shareholders’ equity Total of all stockholders’ equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity’s stockholders’ equity attributable to the parent excludes the amount of stockholders’ equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity. Pfizer Inc.’s total Pfizer Inc. shareholders’ equity as a percentage of total liabilities and equity decreased from Q1 2020 to Q2 2020 but then slightly increased from Q2 2020 to Q3 2020.